Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent.
Ashley Nguyen, Diana S-L Chow, Lei Wu, Yang Angela Teng, Mahua Sarkar, Elizabeth G Toups, James S Harrop, Karl M Schmitt, Michele M Johnson, James D Guest, Bizhan Aarabi, Christopher I Shaffrey, Maxwell Boakye, Ralph F Frankowski, Michael G Fehlings, Robert G Grossman
J Clin Pharmacol 61(9) 1232-1242
摘要
摘要
Riluzole, a benzothiazole sodium channel blocker that received US Food and Drug Administration approval to attenuate neurodegeneration in amyotrophic lateral sclerosis in 1995, was found to be safe and potentially efficacious in a spinal cord injury (SCI) population, as evident in a phase I clinical trial. The acute and progressive nature of traumatic SCI and the complexity of secondary injury processes can alter the pharmacokinetics of therapeutics. A 1-compartment with first-order elimination population pharmacokinetic model for riluzole incorporating time-dependent clearance and volume of distribution was developed from combined data of the phase 1 and the ongoing phase 2/3 trials. This change in therapeutic exposure may lead to a biased estimate of the exposure-response relationship when evaluating therapeutic effects. With the developed model, a rational, optimal dosing scheme can be designed with time-dependent modification that preserves the required therapeutic exposure of riluzole.
KM 提取结果
0 个 Figure · 0 个 KM 面板